Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
103 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Advanz Pharma Belgium from Sint-Joost-ten-Node, company number BE0833413211, closed financial year 2025 with a result of € 27,607 after tax. For that financial year Advanz Pharma Belgium recorded a gross margin of € 288,375 and equity of € 181,026. Compared with financial year 2024, the result moved from € 13,595 to € 27,607. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 15, 2026.
€ 181,026
▲ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 27,607
▲ 103% vs 2024
Profit after tax over the fiscal year.
€ 300,920
▲ 132% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 169,026.
People and assets in 2025
1.5
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 262,469
▼ 35% vs 2024
€ 175,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 157,609
▲ € 126,737 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 22,035
▼ 77% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 363,448 | € 419,665 | € 444,601 | € 288,375 | ▼ 35% |
| Profit after taxes | € 30,675 | € 30,068 | € 13,595 | € 27,607 | ▲ 103% |
| Equity | € 109,758 | € 139,825 | € 153,420 | € 181,026 | ▲ 18% |
| Total debts | € 104,102 | € 158,026 | € 128,018 | € 184,344 | ▲ 44% |
| Cash | - | € 176,252 | € 129,595 | € 300,920 | ▲ 132% |
| Retained profit | € 97,758 | € 127,825 | € 141,420 | € 169,026 | ▲ 20% |
| Balance sheet total | € 213,860 | € 297,851 | € 281,438 | € 365,371 | ▲ 30% |
| Employees (FTE) | 2 | 1 | 2 | 1.5 | ▼ 0.5 |
Key figures of Advanz Pharma Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Advanz Pharma Belgium?
What happened at Advanz Pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 27,607 (▲ 103% vs 2024). Source: NBB ↗
- Andreas Stickler became a director. NBB
- Simon Tuckler became a director. NBB
- New establishment in Sint-Joost-ten-Node. KBO
- Start of the company according to the CBE. KBO
In short
From € 30,675 profit in 2022 to € 27,607 profit in 2025.
Paid € 30,902 in corporate taxes since 2022.
Best year ever: 2022, with € 30,675 profit.
On average € 192,200 of value added per employee in 2025.
A new publication or filing at Advanz Pharma Belgium? We notify you, reason included.
Follow Advanz Pharma BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Advanz Pharma Belgium are Simon Tuckler and Andreas Stickler.
Directors
According to the 2025 annual accounts
Simon Tuckler
Director
since 2020
Andreas Stickler
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Sint-Lazaruslaan 4-10
1210 Sint-Joost-ten-Node
Sint-Lazaruslaan 4-10 ET6
1210 Sint-Joost-ten-Node
Active since 3 February 2011
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 103 companies are registered at this address.
All companies at this address →Energia
€ 970,536 gross margin · 2025
Aurorium Belgium 2
€ 9.5 million revenue · 2025
HASBRO BELGIUM
€ 658,256 gross margin · 2025
Agra CEAS CONSULTING-Bureau Européen de Recherches
€ 1.5 million gross margin · 2023
BMC Software Belgium
€ 2 million gross margin · 2026
+98 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0833.413.211
- VAT number
- BE 0833.413.211
- Registered office
- Sint-Lazaruslaan 4-10, 1210 Sint-Joost-ten-Node
- Names & denominations
- Advanz Pharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 February 2011
- Peppol
- Active · Active since 21 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering